Nanoform Finland Plc
December 10, 2021
04.45 p.m. Finnish time / 03.45 p.m. Swedish time
Nanoform financial calendar for 2022
Helsinki, Finland – In this company announcement Nanoform provides its financial calendar for 2022, which include the planned publication dates of its financial reports, Annual Report and Annual General Meeting.
Planned publication dates for Nanoform's financial reports in 2022:
- report for Q4 2021 and full year 2021: 22 February 2022
- report for Q1 2022: 24 May 2022
- report for Q2 2022 and half-year 2022: 25 August 2022
- report for Q3 2022 and January-September 2022: 29 November 2022
- report for Q4 2022 and full year 2022: 28 February 2023
Nanoform plans to publish its Annual Report for the year 2021, which includes the review by the Board of Directors and the audited annual accounts, latest end of March 2022.
Nanoform’s Annual General Meeting 2022 is planned to be held on 12 April 2022.
For further information, please contact:
Albert Hæggström, CFO
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.